Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annette Bak

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Journal of Medicinal Chemistry|June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Pain|March 14, 2008
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humansNarender R Gavva, James J S Treanor, Andras Garami, et al.
Cancer Research|October 12, 2010
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell linesMarc Payton, Tammy L Bush, Grace Chung, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 27, 2007
Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockadeNarender R Gavva, Anthony W Bannon, David N Hovland, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Journal of Medicinal Chemistry|March 26, 2014
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetesTesfaye Biftu, Ranabir Sinha-Roy, Ping Chen, et al.
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Medicinal Chemistry|June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Pain|March 14, 2008
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humansNarender R Gavva, James J S Treanor, Andras Garami, et al.
Cancer Research|October 12, 2010
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell linesMarc Payton, Tammy L Bush, Grace Chung, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 27, 2007
Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockadeNarender R Gavva, Anthony W Bannon, David N Hovland, et al.
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Journal of Medicinal Chemistry|March 26, 2014
Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetesTesfaye Biftu, Ranabir Sinha-Roy, Ping Chen, et al.
Journal of Medicinal Chemistry|May 14, 2015
Discovery of N-(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of aurora kinases with activity against multidrug-resistant cancer cell linesStephanie Geuns-Meyer, Victor J Cee, Holly L Deak, et al.
Journal of Medicinal Chemistry|August 6, 2010
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitorVictor J Cee, Laurie B Schenkel, Brian L Hodous, et al.
Pageof 4